Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of marstacimab, a study medicine, for treating hemophilia in male pediatric patients aged 1 to 17 years. The study focuses on severe Hemophilia A and moderately severe to severe Hemophilia B, including participants with or without inhibitors. Enrollment is done sequentially by age groups starting with adolescents, then children aged 6 to 11 years, followed by children aged 1 to 5 years. All participants will receive weekly subcutaneous injections of marstacimab, initially administered at the study site with subsequent doses given either at home or at the study site over a 12-month treatment period. The study compares participants experiences during treatment to their historical bleeding and treatment records to assess how marstacimab may help prevent bleeding episodes common in hemophilia. Participants will be involved for about 14 months, including a screening period of roughly one month, 12 months of treatment, and a one-month follow-up. They will attend at least 10 study visits, with the option of completing two visits at home if regulations allow, and receive six scheduled phone calls approximately every two months. Researchers will monitor bleeding rates, safety events, immune responses, joint health, and quality of life during this time.
Actively Recruiting
Researchers are studying the use of LSALT peptide to prevent or reduce acute kidney injury AKI in patients undergoing on-pump cardiac surgery. This trial evaluates how often AKI occurs within 7 days after such surgery, using established kidney function criteria. The study is a randomized, double-blind, placebo-controlled Phase 2 trial involving patients at risk of AKI due to their kidney function or other health factors. Participants will be randomly assigned to receive either the LSALT peptide or a placebo. The LSALT peptide is given intravenously at 10 mg over one hour twice daily for five days, starting at least one hour before anesthesia begins. The placebo group receives a matching saline solution on the same schedule. Standard care continues alongside the study treatments, and safety is closely monitored by an independent board. Throughout the study, participants will have daily physical exams, vital sign checks, and urine output monitoring during the treatment period and shortly after. Kidney function tests and biomarker assessments occur at baseline and regularly through 28 days after surgery. Adverse events are recorded daily during treatment and on follow-up days. The study tracks kidney injury severity, need for kidney replacement therapy, mortality, hospital stay length, and other health outcomes to understand the treatments effects.
Actively Recruiting
Researchers are studying a new drug called ALE.F02 to see if it can protect and preserve kidney function in people with antineutrophil cytoplasmic antibody ANCA associated vasculitis AAV. AAV is an autoimmune disease where the bodys immune system attacks small blood vessels, often affecting the kidneys. This Phase 2 trial aims to evaluate the safety, tolerability, and kidney-protective effects of ALE.F02 when added to standard therapy for rapidly progressive glomerulonephritis RPGN caused by AAV. Participants will be randomly assigned to one of four groups standard treatment plus low, high, or maximum dose ALE.F02 infusions, or standard treatment plus placebo infusions. The treatment period lasts 24 weeks, during which participants receive 13 intravenous infusions alongside standard therapies like Rituximab, glucocorticoids, or cyclophosphamide. The study includes detailed monitoring such as blood and urine tests, pharmacokinetics, antidrug antibody testing, biomarker measurements, pregnancy tests for women, and lung CT scans at baseline and Week 24 if lung involvement is detected. During the study, participants will undergo physical exams and provide samples to assess kidney function and safety. Researchers will measure the primary outcome of safety and tolerability of ALE.F02 up to one year. Secondary outcomes include changes in kidney function markers like estimated glomerular filtration rate eGFR and urine protein levels up to 52 weeks. Participants exposure to glucocorticoids and immunosuppressants will also be tracked. The total study duration extends through treatment and follow-up, with ongoing assessments to understand the drugs effects and safety profile.